Advantest Corporation (TSE: 6857, NYSE: ATE) today announced that its terahertz spectroscopic imaging system TAS7500, which utilizes Advantest’s THz wave technology, has been adopted by Astellas Pharma Inc.
The TAS7500 system enables non-destructive, contact-free spectroscopic analysis and imaging of the inner structures of pharmaceutical products. The system can analyze pharmaceuticals in liquid, powder or solid form, and evaluate crystalline forms, chemical constituents, density, and other characteristics. The system can also produce 2D and 3D images of tablet coating layer thickness and density distribution, as well as cross-sections of multi-layer tablets.
Pharmaceutical firms are developing increasingly complex products, including the recent development of multi-layer tablets that deliver active ingredients more effectively. Manufacturers face a serious challenge in the speedy analysis of the crystalline forms and chemical constituents of promising pharmaceutical materials. The spectroscopic analysis and imaging functions offered by the TAS7500 enable fast, simple, high-throughput drug analysis that contributes to speedier R&D and scale-up.
Wataru Momose, Senior Researcher at Astellas’s Pharmaceutical Research and Technology Labs, said, “The TAS7500 is compact and fits on a desktop. It offers a good selection of spectroscopic analysis (transmission, reflection, ATR [Attenuated Total Reflection]) and imaging functions, and has stable, high-speed measurement capabilities. At present, the most widely used PAT 1 tools are near-infrared spectroscopy and Raman spectroscopy 2, but the TAS7500, based on THz wave technology, is very useful in further improving drug R&D efficiency.”Kazuhiro Sako, Ph.D., Vice President, Pharmaceutical Research and Technology Labs also expressed high hopes for the improved drug R&D efficiency offered by the TAS7500, saying, “Astellas has an increasingly important role in developing and rapidly delivering high-quality pharmaceuticals to patients. Making full use of new analytical devices like this, we aim to contribute even more to people’s health around the world via highly effective and reliable pharmaceutical products.”
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV